Smart Calls with Smartkarma | Henlius Biotech (2696 HK): Profitability, Global Momentum, and Pipeline Strength

Henlius is among the few Chinese biopharma firms to turn profitable—with solid fundamentals, expanding global approvals (incl. EU & Southeast Asia), and an active late-stage pipeline.

Pranav Rao speaks with Criss Wang to explore the long-term upside potential (~20–50%), key risks like biosimilar VBP, and what investors should watch as sentiment drives sector rallies.

Like what you heard? Share this episode and follow us for more Smart Calls.

Read Criss’s full Insight - https://skr.ma/fUAck

Criss Wang - http://on.skr.ma/4lZWC5A

Henlius Biotech - http://on.skr.ma/3IUTCJo

This podcast is provided for general informational and entertainment purposes only, and is not intended to provide financial, investment or other professional advice. Views expressed by third parties do not necessarily represent Smartkarma’s views. Smartkarma assumes no responsibility or liability for the accuracy, compliance or completeness of the podcast or the information it contains. Users should not rely on the podcast or the information it contains when making individual, business or other strategic decisions and should always consult a qualified expert or professional adviser.